Wound healing remains a therapeutic challenge, particularly in chronic and infected wounds, where poor local drug retention, persistent inflammation, oxidative stress, microbial burden, and delayed tissue regeneration reduce the effectiveness of conventional treatments. Solid lipid nanoparticles (SLNs) have emerged as promising lipid-based nanocarriers for topical wound therapy because they combine biocompatibility, protection of labile therapeutic agents, improved local retention, and sustained drug release. This mini-review critically discusses the role of SLNs in modern wound-healing strategies, with emphasis on formulation design, physicochemical properties, mechanisms of action, therapeutic applications, and translational challenges. A narrative literature search was conducted using PubMed, Scopus, and Web of Science to identify relevant studies on SLN preparation methods, wound-healing mechanisms, topical delivery, safety, and clinical translation. SLNs may enhance wound repair through several interconnected mechanisms, including improved wound-bed retention, controlled drug release, interaction with skin and wound barriers, modulation of inflammatory and oxidative pathways, antimicrobial effects, cellular uptake, fibroblast activation, collagen deposition, angiogenesis, and re-epithelialization. Compared with liposomes and polymeric nanoparticles, SLNs offer a practical balance between biocompatibility, physical stability, controlled release, scalability, and cost-effectiveness. However, their clinical translation is still limited by restricted drug loading, lipid polymorphism, formulation instability, sterilization challenges, batch-to-batch variability, and insufficient clinical evidence. Future SLN-based wound therapies may benefit from stimuli-responsive release, artificial intelligence-assisted formulation optimization, personalized wound care, multifunctional theranostic systems, and combination therapy approaches. Nevertheless, standardized evaluation methods, long-term safety studies, scalable manufacturing, and well-designed clinical investigations are required to advance SLNs from experimental wound-healing systems toward clinically applicable products.